Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes

  1. Amanda R Dicks
  2. Grigory I Maksaev
  3. Zainab Harissa
  4. Alireza Savadipour
  5. Ruhang Tang
  6. Nancy Steward
  7. Wolfgang Liedtke
  8. Colin G Nichols
  9. Chia-Lung Wu
  10. Farshid Guilak  Is a corresponding author
  1. Washington University in St. Louis, United States
  2. Regeneron Pharmaceuticals, United States
  3. University of Rochester, United States

Abstract

Mutations in the TRPV4 ion channel can lead to a range of skeletal dysplasias. However, the mechanisms by which TRPV4 mutations lead to distinct disease severity remain unknown. Here, we use CRISPR-Cas9-edited human induced pluripotent stem cells (hiPSCs) harboring either the mild V620I or lethal T89I mutations to elucidate the differential effects on channel function and chondrogenic differentiation. We found that hiPSC-derived chondrocytes with the V620I mutation exhibited increased basal currents through TRPV4. However, both mutations showed more rapid calcium signaling with a reduced overall magnitude in response to TRPV4 agonist GSK1016790A compared to wildtype. There were no differences in overall cartilaginous matrix production, but the V620I mutation resulted in reduced mechanical properties of cartilage matrix later in chondrogenesis. mRNA sequencing revealed that both mutations upregulated several anterior HOX genes and downregulated antioxidant genes CAT and GSTA1 throughout chondrogenesis. BMP4 treatment upregulated several essential hypertrophic genes in WT chondrocytes; however, this hypertrophic maturation response was inhibited in mutant chondrocytes. These results indicate that the TRPV4 mutations alter BMP signaling in chondrocytes and prevent proper chondrocyte hypertrophy, as a potential mechanism for dysfunctional skeletal development. Our findings provide potential therapeutic targets for developing treatments for TRPV4-mediated skeletal dysplasias.

Data availability

All RNAseq data files generated and reported in this study are available on GEO (accession number GSE225446, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225446).

The following data sets were generated

Article and author information

Author details

  1. Amanda R Dicks

    Department of Biomedical Engineering, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  2. Grigory I Maksaev

    Department of Cell Biology and Physiology, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  3. Zainab Harissa

    Department of Biomedical Engineering, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  4. Alireza Savadipour

    Department of Orthopedic Surgery, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  5. Ruhang Tang

    Department of Orthopedic Surgery, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  6. Nancy Steward

    Department of Orthopedic Surgery, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
  7. Wolfgang Liedtke

    Regeneron Pharmaceuticals, Tarrytown, United States
    Competing interests
    Wolfgang Liedtke, Patents on TRPV4 inhibitors have been licensed to TRPblue. Dr. Liedtke is an employee of Regeneron Pharmaceuticals.(US Patents 9,701,675; 10,329,265; and 11,014,896)..
  8. Colin G Nichols

    Department of Cell Biology and Physiology, Washington University in St. Louis, St Louis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4929-2134
  9. Chia-Lung Wu

    Department of Orthopaedics and Rehabilitation, University of Rochester, Rochester, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9598-7036
  10. Farshid Guilak

    Department of Orthopedic Surgery, Washington University in St. Louis, St Louis, United States
    For correspondence
    guilak@wustl.edu
    Competing interests
    Farshid Guilak, Patents on TRPV4 inhibitors licensed to TRPblue Inc. (US Patents 9,701,675; 10,329,265; and 11,014,896)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7380-0330

Funding

National Institutes of Health (AG15768)

  • Farshid Guilak

National Institutes of Health (AG46927)

  • Farshid Guilak

National Institutes of Health (ar072999)

  • Farshid Guilak

National Institutes of Health (AR075899)

  • Chia-Lung Wu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Dicks et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,262
    views
  • 171
    downloads
  • 13
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Amanda R Dicks
  2. Grigory I Maksaev
  3. Zainab Harissa
  4. Alireza Savadipour
  5. Ruhang Tang
  6. Nancy Steward
  7. Wolfgang Liedtke
  8. Colin G Nichols
  9. Chia-Lung Wu
  10. Farshid Guilak
(2023)
Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes
eLife 12:e71154.
https://doi.org/10.7554/eLife.71154

Share this article

https://doi.org/10.7554/eLife.71154

Further reading

    1. Developmental Biology
    2. Stem Cells and Regenerative Medicine
    Joseph A Bisson, Miriam Gordillo ... Todd Evans
    Research Article

    Haploinsufficiency for GATA6 is associated with congenital heart disease (CHD) with variable comorbidity of pancreatic or diaphragm defects, although the etiology of disease is not well understood. Here, we used cardiac directed differentiation from human embryonic stem cells (hESCs) as a platform to study GATA6 function during early cardiogenesis. GATA6 loss-of-function hESCs had a profound impairment in cardiac progenitor cell (CPC) specification and cardiomyocyte (CM) generation due to early defects during the mesendoderm and lateral mesoderm patterning stages. Profiling by RNA-seq and CUT&RUN identified genes of the WNT and BMP programs regulated by GATA6 during early mesoderm patterning. Furthermore, interactome analysis detected GATA6 binding with developmental transcription factors and chromatin remodelers, suggesting cooperative regulation of cardiac lineage gene accessibility. We show that modulating WNT and BMP inputs during the first 48 hr of cardiac differentiation is sufficient to partially rescue CPC and CM defects in GATA6 heterozygous and homozygous mutant hESCs. This study provides evidence of the regulatory functions for GATA6 directing human precardiac mesoderm patterning during the earliest stages of cardiogenesis to further our understanding of haploinsufficiency causing CHD and the co-occurrence of cardiac and other organ defects caused by human GATA6 mutations.

    1. Cell Biology
    2. Stem Cells and Regenerative Medicine
    Liyi Wang, Shiqi Liu ... Tizhong Shan
    Research Article

    Conjugated linoleic acids (CLAs) can serve as a nutritional intervention to regulate quality, function, and fat infiltration in skeletal muscles, but the specific cytological mechanisms remain unknown. Here, we applied single-nucleus RNA-sequencing (snRNA-seq) to characterize the cytological mechanism of CLAs regulates fat infiltration in skeletal muscles based on pig models. We investigated the regulatory effects of CLAs on cell populations and molecular characteristics in pig muscles and found CLAs could promote the transformation of fast glycolytic myofibers into slow oxidative myofibers. We also observed three subpopulations including SCD+/DGAT2+, FABP5+/SIAH1+, and PDE4D+/PDE7B+ subclusters in adipocytes and CLAs could increase the percentage of SCD+/DGAT2+ adipocytes. RNA velocity analysis showed FABP5+/SIAH1+ and PDE4D+/PDE7B+ adipocytes could differentiate into SCD+/DGAT2+ adipocytes. We further verified the differentiated trajectory of mature adipocytes and identified PDE4D+/PDE7B+ adipocytes could differentiate into SCD+/DGAT2+ and FABP5+/SIAH1+ adipocytes by using high intramuscular fat (IMF) content Laiwu pig models. The cell-cell communication analysis identified the interaction network between adipocytes and other subclusters such as fibro/adipogenic progenitors (FAPs). Pseudotemporal trajectory analysis and RNA velocity analysis also showed FAPs could differentiate into PDE4D+/PDE7B+ preadipocytes and we discovered the differentiated trajectory of preadipocytes into mature adipocytes. Besides, we found CLAs could promote FAPs differentiate into SCD+/DGAT2+ adipocytes via inhibiting c-Jun N-terminal kinase (JNK) signaling pathway in vitro. This study provides a foundation for regulating fat infiltration in skeletal muscles by using nutritional strategies and provides potential opportunities to serve pig as an animal model to study human fat infiltrated diseases.